Trial
NCT01693653
Tocilizumab for the Treatment of Behcet's Syndrome
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Genentech, Inc.
Condition
Behcet Syndrome
Intervention
Tocilizumab
Why stopped
low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-15